Genetic Immunity is a US clinical-stage biotechnology company focusing on the discovery, development and commercialization of a new class of therapeutic vaccines ("Immune Therapies") for the treatment of chronic viral infections (HIV, HPV), cancer and allergies. Our Immune Therapies are designed to intensify and boost specific immune response to modify or control these presently incurable diseases. We believe our products will allow people to live better, healthier and longer lives.
Our proprietary immunotherapy platform is composed of an pDNA (plasmid DNA) expressing multiple disease specific antigens, a nanomedicine formulation encapsulating the pDNA and a topical administration device which targets the formulation transdermally to dendritic (Langerhans) cells of the skin. Our platform technologies support the rapid and cost-effective development of novel biologic products for several indications and provides tools for the selection of an optimal, patient specific treatment regimen.
Our Lead Product Candidate, a therapeutic vaccine for the treatment of HIV is effective in boosting immune response to kill HIV-infected cells. Our preclinical, Phase I, Phase I/II and Phase II trials have demonstrated HIV-specific T-cells immune response and boosting, and the killing of HIV-infected cells. DermaVir has an excellent safety profile. Our goal is to provide DermaVir as a co-treatment option to antiretroviral therapy (ART), and, upon the completion of an additional clinical trial, to demonstrate efficacy in ART resistant patients, thereby opening a safe, effective new treatment paradigm.
In addition to HIV we also work on an extensive pipeline including therapeutic treatments for cancer, the human papillomavirus, MAGE, allergies and more.
Please see our pipeline of virus-associated cancers and warts in discovery phase section of the website.
Therapeutic Vaccine for treatment of HIV, referred to as
“DermaVir”, is effective in boosting immune response which kills
HIV-infected cells. Human clinical trials have demonstrated vaccine
is capable of killing HIV-infected cells. DermaVir has a safety
profile similar to vaccines used in healthy adults and children.
DermaVir can also be a co-treatment option if administered with
Attention. There is a risk that unverified members are not actually members of the team
$73 692 257
$138 977 025
This offer is based on information provided solely by the offeror and other publicly available information. The token sale or exchange event is entirely unrelated to ICOholder and ICOholder has no involvement in it (including any technical support or promotion). Token sales listed from persons that ICOholder has no relationship with are shown only to help customers keep track of the activity taking place within the overall token sector. This information is not intended to amount to advice on which you should rely. You must obtain professional or specialist advice or carry out your own due diligence before taking, or refraining from, any action on the basis of the content on our site. Any terms and conditions entered into by contributors in respect of the acquisition of Tokens are between them and the issuer of the Token and ICOholder is not the seller of such Tokens. ICOholder has no legal responsibility for any representations made by third parties in respect of any Token sale and any claim for breach of contract must also be made directly against the Token issuing entity listed herein.
If you have any concerns about the nature, propriety or legality of this token sale or the persons involved in it please contact [email protected] with detailed information about your concerns.